Search

Your search keyword '"Ch'ng Sydney"' showing total 544 results

Search Constraints

Start Over You searched for: Author "Ch'ng Sydney" Remove constraint Author: "Ch'ng Sydney"
544 results on '"Ch'ng Sydney"'

Search Results

1. Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

3. The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

4. Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

5. ASO Visual Abstract: The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma: An Australian Cohort

8. Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

10. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

12. ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging

17. Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma

30. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

31. Long-term survival across Breslow thickness categories: findings from a population-based study of 210 042 Australian melanoma patients.

33. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting

34. A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).

35. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma

37. Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies

42. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

48. Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

Catalog

Books, media, physical & digital resources